ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
- First Posted Date
- 2007-05-23
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 102
- Registration Number
- NCT00477529
- Locations
- 🇺🇸
Nebraska Methodist Hospital, Omaha, Nebraska, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Drug: CC-5013 (lenalidomide)
- First Posted Date
- 2007-05-16
- Last Posted Date
- 2009-09-02
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 26
- Registration Number
- NCT00474188
- Locations
- 🇺🇸
Washington County Hospital, The Center for Clinical Research, Hagerstown, Maryland, United States
🇺🇸Oncology & Hematology Specialists, PA, Denville, New Jersey, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia
- Conditions
- Myelofibrosis With Myeloid MetaplasiaMyeloid MetaplasiaMyelofibrosis
- Interventions
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 88
- Registration Number
- NCT00463385
- Locations
- 🇦🇹
Medical University of Vienna, Department of Internal Medicine, Hematology, Vienna, Austria
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸New York Presbyterian HospitalWeill Medical College of Cornell University, New York, New York, United States
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: MRZ 0.5 mg/m^2
- First Posted Date
- 2007-04-17
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 15
- Registration Number
- NCT00461045
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes
- First Posted Date
- 2007-04-09
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Celgene
- Target Recruit Count
- 34
- Registration Number
- NCT00458159
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Indiana University Medical Center, Indianapolis, Indiana, United States
🇺🇸Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
First Line Therapy for Patients With Metastatic Breast Cancer
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 123
- Registration Number
- NCT00456846
- Locations
- 🇨🇦
BC Cancer Agency-Burnaby, Burnaby, British Columbia, Canada
🇨🇦Mount Sinai Hospital, Toronto, Ontario, Canada
🇨🇦The Royal Victoria Hospital, Barrie, Ontario, Canada
Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 499
- Registration Number
- NCT00452569
- Locations
- 🇵🇱
Klinika Hematologii Nowotworow Krwi i Transplantacji - Szpiku Akademii Medycznej, Wroclaw, Poland
🇮🇳Department of Medical Oncology/Regional Cancer Centre, Trivandrum, India
🇮🇳Department of Medical Oncology, Deenanath Mangeshkar Hospital, Pune, India
A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease
- Conditions
- Crohn's Disease
- First Posted Date
- 2007-03-12
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 90
- Registration Number
- NCT00446433
- Locations
- 🇺🇸
Advanced Clinical Therapeutics, Tucson, Arizona, United States
🇺🇸Washington Hospital Center Physicians Office Building, Washington, District of Columbia, United States
🇺🇸Advanced Clinical Research Institute, Anaheim, California, United States
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
- First Posted Date
- 2007-01-25
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Celgene
- Target Recruit Count
- 131
- Registration Number
- NCT00426764
- Locations
- 🇺🇸
Hematology Oncology Assoc. of IL Orchard Research LLC, Chicago, Illinois, United States
🇩🇪Charite Universitatsmedizin Berlin campus Virchow Klinikum Centrum fur Tumormedizin, Berlin, Germany
🇪🇸Hospital Universitario Vall D Hebron, Barcelona, Spain
A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 351
- Registration Number
- NCT00424047
- Locations
- 🇮🇪
University Hospital GalwayHaematology Department, Galway, Co. Galway, Ireland
🇨🇭Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
🇵🇱Institute of Haematology and Blood Transfusion, Warsaw, Poland